Enovis Corporation (NYSE:ENOV) Receives Average Rating of “Moderate Buy” from Brokerages

Enovis Corporation (NYSE:ENOV) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $44.50.

ENOV has been the subject of a number of recent analyst reports. William Blair assumed coverage on Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Evercore reaffirmed an “outperform” rating and set a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. Zacks Research downgraded Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday. Wells Fargo & Company lowered their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th.

Enovis Stock Performance

Shares of Enovis stock opened at $22.60 on Monday. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The stock’s fifty day moving average is $23.23 and its two-hundred day moving average is $23.86. Enovis has a 52 week low of $19.14 and a 52 week high of $36.82. The company has a market capitalization of $1.30 billion, a PE ratio of -1.14 and a beta of 1.39.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts expect that Enovis will post 3.12 earnings per share for the current year.

Insider Activity

In other news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction on Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders acquired 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enovis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP purchased a new stake in shares of Enovis in the 3rd quarter valued at $83,435,000. Paradigm Capital Management Inc. NY lifted its position in Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the period. AQR Capital Management LLC lifted its position in Enovis by 682.6% during the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the period. Front Street Capital Management Inc. boosted its holdings in Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its holdings in Enovis by 130.8% in the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after purchasing an additional 342,556 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.